Skip to main content
. 2022 Jun 8;53(10):4316–4323. doi: 10.1017/S003329172200099X

Table 1.

Demographic and clinical characteristics at baseline of participants with tests on differences between both ITT and ART conditions

All patients
N = 198
ITT
TAU
N = 53
ITT
ST
N = 58
ITT
ST + P
N = 61
ITT
N = 172
pa
ART
TAU
N = 83
ART
ST
N = 42
ART
ST + P
N = 44
ART
N = 169
pa
Age at referral (mean, s.d.) 21.3 (2.9) 21.3 (3.3) 21.7 (2.9) 21.2 (2.6) 0.566 21.4 (3.1) 21.5 (2.9) 21.3 (2.6) 0.978
Male (n;%) 162 (82%) 41 (77%) 48 (83%) 52 (84%) 0.639 63 (76%) 36 (86%) 39 (87%) 0.227
Caucasian (n;%) 137 (71%) 37 (70%) 46 (79%) 41 (66%) 0.260 60 (72%) 30 (71%) 33 (73%) 0.980
Secondary school finished (n;%) 105 (53%) 29 (55%) 30 (52%) 38 (61%) 0.557 44 (53%) 22 (52%) 28 (62%) 0.551
Strauss Carpenter prognostic scale (mean, s.d.) 39.7 (10.8) 42.5 (10.3) 38.2 (10.2) 40.7 (11.8) 0.111 41.2 (10.0) 38.3 (10.5) 40.9 (12.8) 0.357
Premorbid adjustments scale (mean, s.d.) 14.5 (6.1) 15.4 (6.4) 14.5 (5.9) 14.2 (5.8) 0.541 15.0 (6.1) 14.7 (6.1) 13.6 (5.8) 0.442
Duration untreated psychosis 1 year or longer (n; %) 59 (30%) 13 (25%) 18 (31%) 19 (31%) 0.700 22 (27%) 12 (29%) 15 (33%) 0.717
Type of onset (n;%)
Acute 23 (12%) 6 (11%) 5 ( 9 %) 11 (18%) 0.137 11 (13%) 3 ( 7%) 8 (18%) 0.227
Subacute 70 (35%) 22 (42%) 15 (26%) 23 (37%) 29 (35%) 11 (26%) 18 (41%)
Insidious 104 (53%) 25 (47%) 38 (65%) 27 (45%) 43 (52%) 28 (67%) 18 (41%)
Onset before age 18 (n;%) 60 (30%) 16 (30%) 13 (22%) 20 (32%) 0.458 22 (27%) 12 (29%) 14 (31%) 0.857
PANSS positive symptoms score (mean s.d.) 20.7 (7.6) 20.6 (7.5) 19.7 (7.8) 21.4 (7.2) 0.494 21.0 (7.7) 19.0 (7.4) 21.2 (7.1) 0.282
PANSS negative symptoms score (mean s.d.) 21.5 (7.2) 21.7 (6.0) 21.4 (6.5) 21.2 (7.9) 0.946 22.5 (6.6) 21.4 (6.6) 20.1 (7.2) 0.156
PANSS general psychopathology symptoms score (mean s.d.) 40.7 (10.7) 39.4 (8.6) 40.7 (12.0) 40.2 (10.6) 0.823 41.3 (9.5) 39.0 (12.1) 39.6 (10.7) 0.444
Voluntary admission (n; %) 181 (94%) 51 (96%) 55 (95%) 59 (95%) 0.936 78 (94%) 40 (95%) 44 (98%) 0.625
Non-remission at start outpatient phase (n; %) 19 (10%) 7 (12%) 6 (9%) 6 (9%) 0.853b 11 (12%) 3 ( 7%) 4 ( 8%) 0.593b
a

p = probability in significance test, i.e. analysis of variance or χ2 according to level of measurement.

b

All variables (except the variable ‘non-remission at start outpatient phase’) were tested twice, including and excluding those who where in non-remission chronic at discharge. Not one test yielded significant differences between conditions. Only tests excluding patients with non-remission are reported, except the test for non-remission itself for obvious reasons.